Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NUVL
stocks logo

NUVL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.440
+37.11%
--
--
-1.446
+22.56%
--
--
-1.485
+6.83%
Estimates Revision
The market is revising No Change the revenue expectations for Nuvalent, Inc. (NUVL) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 32.11%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+32.11%
In Past 3 Month
Wall Street analysts forecast NUVL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVL is 139.60 USD with a low forecast of 105.00 USD and a high forecast of 158.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast NUVL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVL is 139.60 USD with a low forecast of 105.00 USD and a high forecast of 158.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
0 Hold
0 Sell
Strong Buy
Current: 106.860
sliders
Low
105.00
Averages
139.60
High
158.00
Current: 106.860
sliders
Low
105.00
Averages
139.60
High
158.00
Truist
Buy
initiated
$140
2025-11-24
Reason
Truist
Price Target
$140
2025-11-24
initiated
Buy
Reason
Truist initiated coverage of Nuvalent with a Buy rating and $140 price target. Nuvalent is emerging as a disruptive precision oncology company poised for commercial transformation by 2026 with two lead candidates approaching potential approval in oncogene-driven non-small cell lung cancer, the analyst tells investors in a research note.
Guggenheim
Brad Canino
Buy
maintain
$125 -> $155
2025-11-18
Reason
Guggenheim
Brad Canino
Price Target
$125 -> $155
2025-11-18
maintain
Buy
Reason
Guggenheim analyst Brad Canino raised the firm's price target on Nuvalent to $155 from $125 and keeps a Buy rating on the shares. The positive neladalkib pivotal data lead the firm to "fully de-risk" its second-to-third line ALK+ NSCLC odds of success estimate and increase its first-line odds to 75%, the analyst tells investors.
Baird
Baird
Outperform
maintain
$112 -> $158
2025-11-18
Reason
Baird
Baird
Price Target
$112 -> $158
2025-11-18
maintain
Outperform
Reason
Baird raised the firm's price target on Nuvalent to $158 from $112 and keeps an Outperform rating on the shares. The firm said its pivotal data in 2L+ALK+NSLC shows strong durability.
Goldman Sachs
Buy
maintain
$120 -> $135
2025-11-18
Reason
Goldman Sachs
Price Target
$120 -> $135
2025-11-18
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Nuvalent to $135 from $120 and keeps a Buy rating on the shares. Neladalkib continues to show best-in-class efficacy vs. other anaplastic lymphoma kinase tyrosine kinase inhibitors in refractory patients, the analyst tells investors in a research note. The firm continues to believe Nuvalent could seek NCCN guideline recommendations for neladalkib in 1L ALK+ NSCLC ahead of its approval there following a similar strategy for zidesamtinib in 1L ROS1+ NSCLC.
H.C. Wainwright
Buy
upgrade
$130 -> $155
2025-11-17
Reason
H.C. Wainwright
Price Target
$130 -> $155
2025-11-17
upgrade
Buy
Reason
H.C. Wainwright raised the firm's price target on Nuvalent to $155 from $130 and keeps a Buy rating on the shares. The firm cites the positive ALKOVE-1 data for the increase. Nuvalent is well positioned to become a commercial entity by the end of 2026, says the analyst, who expects zildesamtinib to receive accelerated approval as a therapy for ROS1-positive lung cancer from the FDA during Q3 of 2026.
Leerink
Outperform
maintain
$140 -> $149
2025-11-17
Reason
Leerink
Price Target
$140 -> $149
2025-11-17
maintain
Outperform
Reason
Leerink raised the firm's price target on Nuvalent to $149 from $140 and keeps an Outperform rating on the shares after the company reported topline results for the AKLOVE-1 pivotal trial evaluating neladalkib. The data provide validation of the target product profile of neladalkib, proving that broader coverage of key single and compound resistance mutations prolongs durability of responses, the analyst tells investors in a research note. The firm added that it believes physicians will begin to consider therapy sequencing options in ALK-positive non-small cell lung cancer and how neladalkib, if approved, could fit into the treatment paradigm.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Nuvalent Inc (NUVL.O) is -18.46, compared to its 5-year average forward P/E of -16.48. For a more detailed relative valuation and DCF analysis to assess Nuvalent Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-16.48
Current PE
-18.46
Overvalued PE
-10.71
Undervalued PE
-22.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-12.95
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-7.28
Undervalued EV/EBITDA
-18.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
146.68
Current PS
0.00
Overvalued PS
618.55
Undervalued PS
-325.19
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 254.34% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 254.34% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

NUVL News & Events

Events Timeline

(ET)
2025-11-19
16:22:18
FDA Accepts Nuvalent's New Drug Application for Zidesamtinib in NSCLC
select
2025-11-19
06:13:34
Nuvalent Sets Secondary Offering of 4.95 Million Shares at $101.00 Each
select
2025-11-17 (ET)
2025-11-17
16:03:50
Nuvalent Reveals $500 Million Class A Common Stock Offering
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-26PRnewswire
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference

  • Company Announcement: Nuvalent, Inc. will have its CEO James Porter and CFO Alexandra Balcom participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 8:30 a.m. ET.

  • Webcast Availability: A live webcast of the event will be accessible on Nuvalent's website and will be archived for 30 days post-presentation.

  • Company Focus: Nuvalent is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for cancer, specifically aimed at overcoming limitations of current treatments for kinase targets.

  • Pipeline Development: The company is advancing a pipeline of investigational candidates for various types of lung cancer and is engaged in multiple discovery-stage research programs.

[object Object]
Preview
8.5
11-25PRnewswire
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders

  • Public Offering Announcement: Nuvalent, Inc. closed its underwritten public offering of 4,950,496 shares of Class A common stock at $101.00 per share, generating approximately $500 million in gross proceeds before expenses.

  • Additional Shares Sold: On November 20, 2025, underwriters exercised their option to purchase an additional 742,574 shares from selling stockholders, with the sale closing on November 24, 2025; Nuvalent did not receive proceeds from this sale.

  • Underwriters and Registration: The offering was managed by J.P. Morgan, Jefferies, TD Cowen, and Cantor, and was conducted under an automatically effective shelf registration statement filed with the SEC.

  • Company Focus: Nuvalent is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for cancer, with a focus on overcoming limitations of existing treatments for specific kinase targets.

[object Object]
Preview
9.0
11-24Newsfilter
Nuvalent Files NDA for Zidesamtinib, Targeting FDA Approval by September 2026
  • NDA Submission: Nuvalent, Inc. has filed a New Drug Application (NDA) for zidesamtinib, targeting adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have received at least one prior ROS1 tyrosine kinase inhibitor. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of September 18, 2026, for this application.
  • Clinical Trial Basis: The NDA submission is based on results from the global ARROS-1 Phase 1/2 clinical trial involving TKI-pretreated patients with advanced ROS1-positive NSCLC. These data were presented at the Presidential Symposium during the IASLC 2025 World Conference on Lung Cancer, indicating the drug's potential efficacy.
  • Drug Characteristics: Zidesamtinib is a novel ROS1-selective inhibitor designed to overcome limitations of existing ROS1 inhibitors, particularly for tumors that have developed resistance. It also features CNS penetrance, potentially improving treatment options for patients with brain metastases.
  • Market Potential: Zidesamtinib has received breakthrough therapy designation for patients previously treated with two or more ROS1 TKIs. This advancement may provide Nuvalent with significant market opportunities in the competitive lung cancer treatment landscape, further solidifying its position in the biopharmaceutical sector.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Nuvalent Inc (NUVL) stock price today?

The current price of NUVL is 106.86 USD — it has decreased -0.04 % in the last trading day.

arrow icon

What is Nuvalent Inc (NUVL)'s business?

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.

arrow icon

What is the price predicton of NUVL Stock?

Wall Street analysts forecast NUVL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVL is 139.60 USD with a low forecast of 105.00 USD and a high forecast of 158.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Nuvalent Inc (NUVL)'s revenue for the last quarter?

Nuvalent Inc revenue for the last quarter amounts to -112.70M USD, increased 47.64 % YoY.

arrow icon

What is Nuvalent Inc (NUVL)'s earnings per share (EPS) for the last quarter?

Nuvalent Inc. EPS for the last quarter amounts to -70462000.00 USD, increased 53.79 % YoY.

arrow icon

What changes have occurred in the market's expectations for Nuvalent Inc (NUVL)'s fundamentals?

The market is revising No Change the revenue expectations for Nuvalent, Inc. (NUVL) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 32.11%.
arrow icon

How many employees does Nuvalent Inc (NUVL). have?

Nuvalent Inc (NUVL) has 142 emplpoyees as of December 05 2025.

arrow icon

What is Nuvalent Inc (NUVL) market cap?

Today NUVL has the market capitalization of 8.30B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free